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Quantitative Evaluation of Biologic Therapy
Options for Psoriasis: A Systematic Review
and Network Meta-Analysis
Zarif K. Jabbar-Lopez1, Zenas Z.N. Yiu2, Victoria Ward3, Lesley S. Exton4, M. Firouz Mohd Mustapa4,
Eleanor Samarasekera5, A. David Burden6, Ruth Murphy7, Caroline M. Owen8, Richard Parslew9,
Vanessa Venning10, Richard B. Warren2 and Catherine H. Smith11
Multiple biologic treatments are licensed for psoriasis. The lack of head-to-head randomized controlled trials
makes choosing between them difficult for patients, clinicians, and guideline developers. To establish their
relative efficacy and tolerability, we searched MEDLINE, PubMed, Embase, and Cochrane for randomized
controlled trials of licensed biologic treatments for skin psoriasis. We performed a network meta-analysis to
identify direct and indirect evidence comparing biologics with one another, methotrexate, or placebo. We
combined this with hierarchical cluster analysis to consider multiple outcomes related to efficacy and tolera-
bility in combination for each treatment. Study quality, heterogeneity, and inconsistency were evaluated. Direct
comparisons from 41 randomized controlled trials (20,561 participants) were included. All included biologics
were efficacious compared with placebo or methotrexate at 3e4 months. Overall, cluster analysis showed
adalimumab, secukinumab, and ustekinumab were comparable in terms of high efficacy and tolerability. Ixe-
kizumab and infliximab were differentiated by very high efficacy but poorer tolerability. The lack of longer term
controlled data limited our analysis to short-term outcomes. Trial performance may not equate to real-world
performance, and so results need to be considered alongside real-world, long-term safety and effectiveness
data. These data suggest that it is possible to discriminate between biologics to inform clinical practice and
decision making (PROSPERO 2015:CRD42015017538).
Journal of Investigative Dermatology (2017) 137, 1646e1654; doi:10.1016/j.jid.2017.04.009
INTRODUCTION
Biologic therapies have revolutionized the treatment of
moderate-severe psoriasis over the last decade. The first
monoclonal antibodies targeting the tumor necrosis factor-
alpha pathway were licensed in 2004 and, more recently,
antibodies to IL-12/23 and IL-17A have been introduced.
Currently, a total of six distinct biologic therapies are licensed
for use in Europe and the USA: adalimumab, etanercept,
infliximab, ixekizumab, secukinumab, and ustekinumab, all
of which perform significantly better than placebo (Galvan-
Banqueri et al., 2013; Lucka et al., 2012; Nast et al., 2015;
Schmitt et al., 2014), thus providing real choice in terms of
treatment options for patients with psoriasis. Given this
choice, the challenge is in deciding which treatment to use
for which patients. Patients and clinicians are reliant on
extrapolating data on average effects from randomized
controlled trials (RCTs) to help inform their decision-making
process. Traditional pairwise meta-analyses of such trials are
useful in summarizing these data; however, their application
to practical clinical decision making is challenging when
there are multiple treatments and multiple outcomes to
consider. The issue is compounded by the paucity of direct
head-to-head active-comparator RCTs needed to inform such
pairwise meta-analyses.
We therefore wished to summarize the available data on
biologic therapies for psoriasis in a meaningful way that can
inform decision making by patients and clinicians. A useful
way of understanding the differences between treatments is
to perform a systematic review of the current evidence and a
network meta-analysis (NMA), where a connecting network
of evidence allows for comparisons to be made between all
available interventions and a relative ranking of treatments
produced (Mills et al., 2013). There are several advantages of
this approach, namely, that the indirect evidence can fill gaps
in the evidence and all comparisons can be considered
simultaneously. In addition, the pooled estimates can provide
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greater statistical power and precision than can be obtained
from individual studies (Leucht et al., 2016).
Six NMAs (Bansback et al., 2009; Gomez-Garcia et al.,
2017; Lin et al., 2012; Reich et al., 2012; Signorovitch et al.,
2015; Woolacott et al., 2006) have been published exam-
ining the relative efficacy of biologics for psoriasis. Treatment
tolerability is an important consideration for patients, with
such concerns directly influencing whether patients adhere to
treatment after initiation (Thorneloe et al., 2016). Tolerability
is not directly measured in clinical trials; however, in a
clinical trial setting, it can be inferred by patients’ willingness
to continue on treatment. Only one NMA (Gomez-Garcia
et al., 2017) has investigated both efficacy and the risk of
adverse events of biologics for psoriasis, and thus far no study
has investigated the efficacy and tolerability of treatments in
combination.
Here we have reviewed the currently available RCT
evidence to assess the efficacy and tolerability of licensed
biologic therapies for skin psoriasis—adalimumab, eta-
nercept, infliximab, secukinumab, ustekinumab, and
ixekizumab—compared with each other, placebo, or meth-
otrexate. We performed an NMA and hierarchical cluster
analysis to rank the biologic therapies in terms of a combi-
nation of both efficacy and tolerability in an objective way.
We also considered the absolute effects of the various treat-
ments to provide meaningful information to support decision
making. This work will also inform the development work for
the updated British Association of Dermatologists’ guidelines
for the use of biologic therapies in psoriasis.
RESULTS
Study selection and characteristics
After deduplication, 5,915 studies were identified on
searching. Forty-five studies were selected for inclusion
(Supplementary Appendix S1 online), presenting data on
direct comparisons from 41 RCTs (20,561 participants) (see
Figure 1). All trials involved patients with moderate-severe
chronic plaque psoriasis; 29 of 41 (71%) studies included
patients with a psoriasis area and severity index (PASI)  12,
7 of 41 (17%) with a PASI  10, and 5 of 41 (12%) with
Figure 1. Flow diagram showing the
identification of literature in the
PRISMA format. RCT, randomized
controlled trial.
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“moderate to severe” disease, not otherwise specified.
Detailed characteristics of the included studies are given in
Supplementary Table S1 (online). Excluded studies are given
in Supplementary Table S2 (online). Most trials (38/41 [93%])
were two-arm studies and the rest were three-arm studies. All
studies included patients with previous conventional systemic
therapy use. Only 12 of 41 (29%) trials excluded patients with
previous biologic therapy use, and in trials that allowed pre-
vious biologic use, the percentages ranged from 1.6 to 64.3%.
Five trials (12%) did not state previous biologic therapy use.
Network structure
Placebo-controlled comparisons were available for all treat-
ments and outcomes. Direct active comparisons between
biologics were limited to ixekizumab, ustekinumab, or
secukinumab versus etanercept, and ustekinumab versus
secukinumab. There were also direct comparisons between
methotrexate and adalimumab or infliximab. Fewer direct
comparisons were available for mean change in dermatology
life quality index (DLQI) (see Figure 2b).
Risk of bias
The risk of bias varied between individual studies, ranging
from low to high (Supplementary Figures S1 and S2 online). A
total of 35 of 41 (85%) RCTs had a low risk of selection bias
and 37 of 41 (90%) had a low risk of performance bias. A
total of 38 of 41 RCTs (93%) had a low risk of detection bias
and 35 of 41 RCTs (85%) had a low risk of attrition bias. All
studies were financially sponsored by the pharmaceutical
industry. There was a low risk of reporting bias. Regarding
publication bias, comparison-adjusted funnel plots suggested
asymmetry between small studies for the outcomes of clear/
nearly clear and PASI 75 at 12 to 16 weeks in relation to
newer versus established treatments. There was no apparent
asymmetry for the studies examining biologic therapies
versus placebo at 12 to 16 weeks for any of the outcomes
(Supplementary Figures S21eS24 online).
Efficacy of biologic treatments at 12 to 16 weeks
All biologic therapies and methotrexate had statistically sig-
nificant increased odds of clear/nearly clear, PASI 75, and
mean change in DLQI compared with placebo at 12 to 16
weeks (Table 1, Supplementary Figures S3eS5 online).
The rankograms in Supplementary Figures S11eS13 (on-
line) show the cumulative probabilities (estimated and pre-
dictive) for clear/nearly clear, PASI 75, and mean change in
DLQI. In terms of clear/nearly clear and PASI 75, ixekizumab
performed best (surface under the cumulative ranking curve
[SUCRA] 99.4) and placebo performed worst (SUCRA 0.0)
(see Relative treatment rankings, Table 2). Secukinumab
performed best (SUCRA 84.3) and placebo worst (SUCRA
0.1) in terms of mean change in DLQI. The rankings calcu-
lated using predictive probabilities were consistent with the
estimated probabilities.
In absolute terms, there was a difference of 112 (95%
confidence interval [CI] 21, 231) more people per 1,000
achieving clear/nearly clear with ixekizumab compared with
secukinumab, or 259 (95% CI 155, 341) more people per
1,000 with ixekizumab compared with ustekinumab. This
equates to a numbers needed to treat of 4 (95% CI 3, 7) for
the ixekizumab-ustekinumab comparison (Table 1).
Tolerability of biologic treatments at 12 to 16 weeks
There were statistically significant increased odds of with-
drawal due to adverse events with infliximab or ixekizumab
compared with placebo (Supplementary Figure S6 online).
Compared with etanercept, infliximab was associated with
statistically significant increased odds of withdrawal due to
adverse events. Ixekizumab was associated with higher odds
of withdrawal compared with adalimumab, ustekinumab,
and secukinumab (Table 1). Ustekinumab performed best
(SUCRA 82.3) and infliximab worst (SUCRA 3.5) (Table 2,
Supplementary Figure S14 online).
Joint rankings of efficacy and tolerability
Using hierarchical clustering, three distinct clusters of treat-
ments were identified with respect to efficacy measured by
clear/nearly clear and mean change in DLQI jointly
(Supplementary Figure S16 online). Adalimumab, infliximab,
ixekizumab, secukinumab, and ustekinumab were all similar
with regard to these two efficacy parameters. Etanercept and
methotrexate formed a separate group that was less effica-
cious in terms of both outcomes. Placebo formed its own
group, characterized by low efficacy.
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Figure 2. Network maps for the main outcomes considered in the review. (a) Clear/nearly clear (minimal residual activity/PASI > 90/0 or 1 on PGA). (b) Mean
change in the dermatology life quality index. (c) Withdrawal due to adverse events, all at 12 to 16 weeks. Nodes and edges are weighted according to number of
studies including that treatment or comparison. ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX, methotrexate; PASI, psoriasis area
and severity index; PBO, placebo; PGA, physician’s global assessment; SEC, secukinumab; UST, ustekinumab.
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Three distinct clusters of treatments were identified when
considering efficacy (clear/near clear) and tolerability (with-
drawal due to adverse events) jointly (Figure 3). Adalimumab,
secukinumab, and ustekinumab formed one cluster,
characterized by high efficacy and tolerability. Infliximab and
ixekizumab formed another cluster, characterized by high effi-
cacy with poorer tolerability. Etanercept, methotrexate, and
placebo formed another cluster, characterized by poorer
Table 1. Network meta-analysis results summary table for the three main outcomes at 12 to 16 weeks: clear/nearly
clear, mean change in DLQI, withdrawal due to adverse events
Biologic
intervention,
outcome Comparison
OR (95% CI)/mean
change (95% CI)
Assumed risk with
comparator, per
1,000 patients1
Corresponding risk
with comparator per
1,000 patients (95% CI)
No. of participants,
direct evidence
(no. of studies)
NNT (95% CI)/NNH
(95% CI)
Clear/nearly clear (minimal residual activity/PASI > 90/0 or 1 on PGA) at 12 to 16 wk
Adalimumab ADA versus PBO 27.53 (16.68, 45.44) 20 341 (235, 463) 2,200 (6 studies) 3 (3, 5)
ADA versus ETA 1.72 (0.95, 3.13) 216 106 (9, 247) 0 (0 studies) NS
Etanercept ETA versus PBO 15.96 (11.52, 22.10) 20 227 (171, 292) 4,897 (12 studies) 5 (4, 6)
Infliximab INF versus PBO 43.27 (22.73, 82.38) 20 451 (298, 609) 1,591 (4 studies) 3 (2, 4)
INF versus ADA 1.57 (0.76, 3.26) 482 112 (68, 270) 0 (0 studies) NS
INF versus ETA 2.71 (1.32, 5.56) 216 212 (51, 389) 48 (1 study) 5 (3, 20)
Ustekinumab UST versus PBO 37.14 (26.96, 51.16) 20 413 (337, 493) 4,221 (9 studies) 3 (2, 3)
UST versus MTX 4.18 (1.90, 9.19) 151 275 (101, 469) 0 (0 studies) 4 (3, 10)
UST versus ETA 2.33 (1.61, 3.37) 216 175 (91, 266) 903 (1 study) 6 (4, 11)
UST versus ADA 1.35 (0.74, 2.45) 482 75 (74, 213) 0 (0 studies) NS
UST versus INF 0.86 (0.42, 1.75) 498 38 (204, 136) 0 (0 studies) NS
Secukinumab SEC versus PBO 72.78 (47.85, 110.69) 20 579 (476, 675) 2,470 (5 studies) 2 (2, 3)
SEC versus MTX 8.20 (3.55, 18.91) 151 442 (236, 620) 0 (0 studies) 3 (2, 5)
SEC versus ETA 4.56 (3.01, 6.91) 216 341 (237, 440) 978 (1 study) 3 (3, 5)
SEC versus ADA 2.64 (1.38, 5.08) 482 229 (80, 343) 0 (0 studies) 5 (3, 13)
SEC versus INF 1.68 (0.78, 3.61) 498 127 (62, 284) 0 (0 studies) NS
SEC versus UST 1.96 (1.29, 2.97) 486 164 (63, 251) 671 (1 study) 6 (4, 16)
Ixekizumab IXE versus PBO 114.84 (72.80, 181.17) 20 682 (579, 768) 3,267 (4 studies) 2 (2, 2)
IXE versus MTX 12.93 (5.53, 30.27) 151 546 (345, 692) 0 (0 studies) 2 (2, 3)
IXE versus ADA 4.17 (2.12, 8.21) 482 313 (182, 402) 0 (0 studies) 4 (3, 6)
IXE versus ETA 7.20 (4.92, 10.53) 216 449 (360, 528) 2,209 (2 studies) 3 (2, 3)
IXE versus INF 2.65 (1.22, 5.79) 498 226 (50, 354) 0 (0 studies) 5 (3, 20)
IXE versus SEC 1.58 (0.92, 2.71) 499 112 (21, 231) 0 (0 studies) NS
IXE versus UST 3.09 (1.89, 5.06) 486 259 (155, 341) 0 (0 studies) 4 (3, 7)
Mean change in DLQI at 12 to 16 wk
Adalimumab ADA versus PBO 7.31 (8.78, 5.82) 1,600 (4 studies)
ADA versus ETA 1.29 (3.52, 0.94) 0 (0 studies)
Etanercept ETA versus PBO 6.01 (7.68, 4.34) 1,076 ( 2 studies)
Infliximab INF versus PBO 8.43 (9.79, 7.06) 1,591 (4 studies)
INF versus ADA 1.13 (3.15, 0.90) 0 (0 studies)
INF versus ETA 2.42 (4.57, 0.26) 0 (0 studies)
Ustekinumab UST versus PBO 8.08 (9.10, 7.06) 2,750 (6 studies)
UST versus MTX 4.86 (7.67, 2.04) 0 (0 studies)
UST versus ETA 2.07 (4.03, 0.11) 0 (0 studies)
UST versus ADA 0.78 (2.58, 1.02) 0 (0 studies)
UST versus INF 0.33 (1.45, 2.11) 0 (0 studies)
Secukinumab SEC versus PBO 8.60 (9.90, 7.30) 1,833 (3 studies)
SEC versus MTX 5.37 (8.30, 2.45) 0 (0 studies)
SEC versus ETA 2.59 (4.70, 0.47) 0 (0 studies)
SEC versus ADA 1.30 (3.28, 0.69) 0 (0 studies)
SEC versus INF 0.17 (2.04, 1.70) 0 (0 studies)
SEC versus UST 0.51 (1.99, 0.96) 675 (1 study)
Ixekizumab IXE versus PBO 8.06 (9.71, 6.41) 1,830 (2 studies)
IXE versus MTX 4.83 (7.93, 1.73) 0 (0 studies)
IXE versus ETA 2.05 (3.66, 0.43) 2,184 (2 studies)
IXE versus ADA 0.76 (2.98, 1.46) 0 (0 studies)
IXE versus INF 0.37 (1.77, 2.51) 0 (0 studies)
IXE versus SEC 0.54 (1.56, 2.64) 0 (0 studies)
IXE versus UST 0.03 (1.92, 1.97) 0 (0 studies)
(continued )
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efficacy and moderate tolerability. The same groupings were
identified when comparing mean change in DLQI with with-
drawaldue toadverse events (SupplementaryFigureS15online).
Inconsistency
Overall tests of consistency and visual inspection of the forest
plots (Supplementary Figures S9 and S10 online) did not
identify statistically significant inconsistency for mean
change in DLQI (c2(2) ¼ 1.45, P ¼ 0.485) (Supplementary
Figure S19 online), or withdrawal due to adverse events
(c2(9) ¼ 5.56, P ¼ 0.783) (Supplementary Figure S20 online).
There was no overall statistically significant inconsistency for
the outcome of clear/nearly clear (c2(9) ¼ 8.84, P ¼ 0.453);
however, visual inspection of the forest plot (Supplementary
Figure S7 online) suggested possible inconsistency (incon-
sistency factor 0.63, 95% CI 0.08, 1.18) in study 6,
comparing infliximab with etanercept (de Vries et al., 2017)
(Supplementary Figure S17 online). Statistically significant
loop inconsistency was identified in the loop containing
etanercept, ustekinumab, and secukinumab. There was sta-
tistically significant evidence of inconsistency for the
outcome of PASI 75 (c2(9) ¼ 22.89, P ¼ 0.006). Visual in-
spection of the PASI 75 forest plot (Supplementary Figure S8
online) generally suggested consistency between direct and
indirect results; however, the effect of methotrexate and/or
Study 40 (Saurat et al., 2008) appeared to be inconsistent.
Loop-specific inconsistency was examined for PASI 75 and
confirmed a significantly raised inconsistency factor in the
placebo-infliximab-methotrexate loop (inconsistency factor
2.31, 95% CI 1.24, 3.39) (Supplementary Figure S18 online).
Subgroup analysis
A predefined subgroup analysis was performed using studies
comparing only licensed biologic doses (Supplementary
Figures S25eS27 online). Relative rankings were the same
as for the main analysis for the efficacy outcomes
(Supplementary Table S4 online). For the outcome of with-
drawal due to adverse events, Etanercept performed best
(SUCRA 77.8) and methotrexate worst (SUCRA 6.7).
DISCUSSION
WehaveperformedacomprehensiveNMAcomparingbiologic
therapies for moderate-severe psoriasis. This NMA includes the
newly licensed anti-IL-17A monoclonal antibody, ixekizumab,
and considers joint rankings of multiple outcomes for psoriasis,
includingDLQI, and to provide absolute effect estimates to help
inform clinical decision making. The identification of three
distinct groups of treatments based on efficacy and tolerability
provides an objective way of considering the relative strengths
and weaknesses of the different biologics.
Of the best overall performing treatments, approximately five
additional patients would need to be treatedwith secukinumab
compared with adalimumab, and six with secukinumab
compared with ustekinumab to achieve clearance or near
Table 1. Continued
Biologic
intervention,
outcome Comparison
OR (95% CI)/mean
change (95% CI)
Assumed risk with
comparator, per
1,000 patients1
Corresponding risk
with comparator per
1,000 patients (95% CI)
No. of participants,
direct evidence
(no. of studies)
NNT (95% CI)/NNH
(95% CI)
Withdrawal due to adverse events at 12 to 16 wk
Adalimumab ADA versus PBO 0.67 (0.40, 1.58) 19 6 (11, 11) 2,200 (6 studies) NS
ADA versus ETA 0.65 (0.33, 1.27) 20 7 (13, 5) 0 (0 studies) NS
Etanercept ETA versus PBO 1.03 (0.67, 1.58) 19 1 (6, 11) 3,464 (9 studies) NS
Infliximab INF versus PBO 2.73 (1.29, 5.78) 19 31 (5, 82) 1,213 (3 studies) 33 (13, 200)
INF versus ADA 4.08 (1.69, 9.88) 26 71 (17, 181) 0 (0 studies) 14 (6, 59)
INF versus ETA 2.66 (1.16, 6.09) 20 31 (3, 90) 48 (1 study) 33 (12, 334)
Ustekinumab UST versus PBO 0.65 (0.41, 1.05) 19 7 (11, 1) 4,221 (9 study) NS
UST versus MTX 0.61 (0.22, 1.68) 47 18 (36, 29) 0 (0 studies) NS
UST versus ETA 0.63 (0.36, 1.12) 20 7 (13, 2) 903 (1 study) NS
UST versus ADA 0.97 (0.48, 1.96) 26 1 (13, 23) 0 (0 studies) NS
UST versus INF 0.24 (0.10, 0.57) 76 56 (68, 31) 0 (0 studies) 18 (33, 15)
Secukinumab SEC versus PBO 0.66 (0.34, 1.26) 19 6 (13, 5) 2,472 (5 studies) NS
SEC versus MTX 0.61 (0.20, 1.86) 47 18 (37, 37) 0 (0 studies) NS
SEC versus ETA 0.64 (0.31, 1.30) 20 7 (14, 6) 980 (1 study) NS
SEC versus ADA 0.98 (0.43, 2.26) 26 0 (14, 30) 0 (0 studies) NS
SEC versus INF 0.24 (0.09, 0.64) 76 56 (68, 26) 0 (0 studies) 18 (39, 15)
SEC versus UST 1.01 (0.48, 2.12) 13 2 (170, 184) 671 (1 study) NS
Ixekizumab IXE versus PBO 1.91 (1.06, 3.45) 19 17 (1, 44) 2,826 (3 studies) 59 (23, 1,000)
IXE versus MTX 1.79 (0.61, 5.21) 47 34 (18, 157) 0 (0 studies) NS
IXE versus ADA 2.86 (1.30, 6.27) 26 40 (7, 116) 0 (0 studies) 25 (9, 143)
IXE versus ETA 1.86 (1.02, 3.39) 20 16 (0, 44) 1,909 (2 studies) NS
IXE versus INF 0.70 (0.27, 1.79) 76 22 (54, 52) 0 (0 studies) NS
IXE versus SEC 2.91 (1.24, 6.82) 11 20 (3, 58) 0 (0 studies) 50 (18, 334)
IXE versus UST 2.94 (1.42, 6.09) 13 25 (6, 63) 0 (0 studies) 40 (16, 167)
Abbreviations: ADA, adalimumab; CI, confidence interval; DLQI, dermatology life quality index; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX,
methotrexate; NNT, numbers needed to treat; NS, non-significant; OR, odds ratio; PBO, placebo; PGA, physician’s global assessment; SEC, secukinumab;
UST, ustekinumab.
1The assumed risk is based on the pooled event rate across all studies of that comparator.
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clearance for an additional patient, with no significant differ-
ence in tolerability. These numbers needed to treat are signifi-
cant compared with, for example, the numbers needed to treat
of 42 for aspirin in prevention of death in acute myocardial
infarction (ISIS-2, 1988). Apart from placebo comparisons, the
absolute differences in mean change in DLQI were small and
below the conventionally clinically significant difference of 4
units on the DLQI scale (Basra et al., 2015) (Table 1).
Ixekizumab, while the most efficacious treatment in terms
of clear/nearly clear, was relatively less well tolerated than
placebo, adalimumab, or secukinumab. In absolute terms,
this equates to an NNH of 25 compared with adalimumab,
and an NNH of 18 compared with secukinumab, implying
that 18 additional people would need to be treated with
ixekizumab compared with secukinumab to result in one
additional withdrawal due to adverse events. It is not clear
what is driving the relatively poor tolerability of ixekizumab
as the reasons for withdrawal were not stated in the published
papers. A possibility is that dose optimization with respect to
efficacy may be at the expense of tolerability. For example, in
rheumatoid arthritis, an increased risk of serious infections
appears to be dose related (Singh et al., 2015). The ixekizu-
mab studies included a range of dosing regimens; however,
all were equivalent to or below the licensed dose, apart from
one small group (n ¼ 28) in the dose-finding study who
received a cumulative dose higher than the current licensed
dose, suggesting that the findings are relevant to clinical
practice. When the data on licensed doses only were
analyzed in the NMA, the position of ixekizumab remained
unchanged in terms of efficacy; however, its ranking in terms
of withdrawal due to adverse events improved from 7th to
6th. The differences may be true differences due to different
doses or may reflect the reduced precision seen in the smaller
network of studies looking at just licensed doses, particularly
for this less frequent outcome. Given this uncertainty, the
data on tolerability should be interpreted cautiously. Simi-
larly, caution should be applied to the interpretation of the
change in DLQI outcome data due to possible variation in
baseline values for this change score.
These findings are broadly consistent with previously
published NMAs on biologics for psoriasis. For example, the
NMA by Gomez-Garcia et al. (2017) suggested that inflix-
imab, secukinumab, and ustekinumab were the most
efficacious treatments in the short term. Our review in-
corporates a wider number of studies as well as the new anti-
IL-17A biologic, ixekizumab, and methotrexate as an
important comparator. Furthermore, we have considered ef-
ficacy as objective (clear/nearly clear) and subjective (DLQI)
outcomes, and jointly ranked these outcomes using cluster
analysis with a proxy marker of tolerability. The rankings are
likely to be robust as the rankings obtained from the pre-
dictive probabilities, taking into account uncertainty, are
consistent with rankings from the estimated probabilities.
There are some key limitations to the interpretation of these
results. In particular, the generalizability is limited to the
populations included in the RCTs. These populations may be
importantly different from patients treated in day-to-day
clinical practice (Garcia-Doval et al., 2012). For complete-
ness, we decided to combine data on all treatment doses;
however, there may be important dose-dependent effects on
efficacy and safety. An individual participant NMA would be
well placed to explore this and other potential sources of
heterogeneity. Furthermore, outcomes at 3e4 months
Table 2. Relative treatment rankings (outcomes at 12 to 16 wk)
Treatment
Clear/nearly clear PASI 75 Mean change in DLQI
Withdrawal due to adverse
events
SUCRA Pr. Best Mean rank SUCRA Pr. Best Mean rank SUCRA Pr. Best Mean rank SUCRA Pr. Best Mean rank
Adalimumab 46.3 0.0 4.8 48.7 0.0 4.6 50.8 3.0 4.4 80.5 29.7 2.4
Etanercept 28.1 0.0 6.0 28.4 0.0 6.0 30.6 0.0 5.9 46.0 0.6 4.8
Infliximab 66.5 0.6 3.3 81.2 16.1 2.3 79.6 30.7 2.4 3.6 0.0 7.8
Ixekizumab 99.2 94.5 1.1 96.4 77.9 1.3 69.9 17.5 3.1 13.9 0 7.0
Methotrexate 15.4 0.0 6.9 14.5 0.0 7.0 14.8 0.0 7.0 47.1 7.5 4.7
Placebo 0.0 0.0 8.0 0.0 0.0 8.0 0.1 0.0 8.0 47.0 0.0 4.7
Secukinumab 85.0 4.9 2.1 79.0 6.0 2.5 84.5 40.3 2.1 79.6 33.1 2.4
Ustekinumab 59.6 0.0 3.8 51.9 0.0 4.4 69.7 8.6 3.1 82.4 29.1 2.2
Bold text indicates the highest ranking treatment for that outcome.
Abbreviations: DLQI, dermatology life quality index; PASI, psoriasis area and severity index; Pr. Best, probability of being best; SUCRA, surface under the
cumulative ranking curve.
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Figure 3. Plot of joint rankings based on hierarchical clustering of the
surface under the cumulative ranking curve (SUCRA) estimates. Combined
estimates of efficacy (clear/nearly clear—minimal residual activity/PASI > 90/
0 or 1 on PGA) and tolerability (withdrawal due to adverse events) at 12 to 16
weeks. ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab;
MTX, methotrexate; PASI, psoriasis area and severity index; PBO, placebo;
PGA, physician’s global assessment; SEC, secukinumab; UST, ustekinumab.
ZK Jabbar-Lopez et al.
Evaluation of Biologic Therapy Options for Psoriasis
www.jidonline.org 1651
represent a relatively short-term timeframe in this chronic
condition that can persist for many years. The withdrawal due
to adverse event results may be less reliable due to the low
number of events (generally between 1 and 2%), reflected in
the wide CI of the estimates (Supplementary Figure S8).
Although the hierarchical cluster analysis results offer an
objective way of combining different outcome measures,
individual patients may prioritize one outcome over another.
There is evidence of small study effects favoring older treat-
ments with respect to the efficacy outcomes of clear/nearly
clear and PASI 75. This could suggest evidence of publication
bias in favor of small studies that show a beneficial effect of
the established comparator, potentially underestimating the
effects of newer treatments.
Consistency and transitivity are important assumptions for
the validity of an NMA. Consistency refers to the level of
agreement between direct and indirect sources of evidence
and transitivity refers to the assumption that available treat-
ment comparisons do not differ with respect to the distribu-
tion of effect modifiers (Chaimani et al., 2013). Transitivity
cannot directly be tested but would be expected to hold as
the characteristics of the patients in the studies are broadly
similar given the requirements for patients to have moderate-
severe psoriasis and to have received previous systemic
therapy. Varying levels of previous biologic use among par-
ticipants in the included studies may be important. Consis-
tency was generally acceptable apart from for PASI 75 where
the results should be interpreted with caution because of
inconsistency within the infliximab-methotrexate-placebo
closed loop. Only two RCTs included a methotrexate arm
(Barker et al., 2011; Saurat et al., 2008). The direct compar-
ison between infliximab and methotrexate comes from the
RESTORE-1 study (Barker et al., 2011) where all patients
were methotrexate-naı¨ve, which is slightly unusual
compared with other studies of biologics, and may over-
estimate the effect of infliximab compared with metho-
trexate. It may also overestimate the effect of methotrexate
compared with studies where patients have previously
received methotrexate. It is also important to remember that
these are average effects and individual patients may expe-
rience different results. Efforts are underway to stratify groups
of patients receiving biologic treatments for psoriasis to pre-
dict which treatments will perform best with which treat-
ments, such as the psoriasis stratification to optimize relevant
therapy initiative (Griffiths et al., 2015).
In terms of research implications, on the basis of these
findings, we would argue that the use of placebo as a
comparator is no longer ethical for RCTs that examine treat-
ment efficacy as there is no clinical equipoise regarding the
short-term relative efficacy of any of the biologic treatments
compared with placebo. These results suggest that, ideally,
direct head-to-head comparisons should be made with ada-
limumab (where there is currently a complete absence of
head-to-head studies), ixekizumab, secukinumab, or usteki-
numab. Clinically, the use of hierarchical cluster analysis in
conjunction with NMA provides an objective simultaneous
assessment of multiple outcomes of efficacy and tolerability
that allows discrimination. Improved efficacy of biologics may
be at the expense of tolerability, and this tradeoff should be
considered in the development and evaluation of new
biologic treatments for psoriasis. Overall, these results need to
be considered alongside real-world, long-term safety and
effectiveness data to inform shared decision making.
MATERIALS AND METHODS
We conducted a systematic review to examine the efficacy and
tolerability of biologic therapies for psoriasis in accordance with the
PRISMA-NMA statement (Hutton et al., 2015). The review protocol
was registered on the PROSPERO international prospective register
of systematic reviews (2015:CRD42015017538) (Supplementary
Table S2). A more detailed description of the methods is given in
Supplementary Appendix S2 (Supplementary methods).
Search and study selection
Thepatient population includedall peoplewith psoriasis of any severity
being treated primarily for their skin disease. RCTswere considered for
inclusion if the intervention consisted of one or more of the following:
adalimumab, etanercept, infliximab, ixekizumab, ustekinumab, and
secukinumab. The comparison arm could consist of any of the listed
biologic therapies above, placebo or methotrexate. Outcomes of in-
terest were decided through simple majority voting by the guideline
development group, including patient representatives. The “critical”
outcomes were those of efficacy: clear/nearly clear (minimal residual
activity/PASI > 90/0 or 1 on physician’s global assessment) and mean
change in DLQI. PASI 75 was considered “important” rather than
“critical.” The primary safety outcome was tolerability, measured by
withdrawal due to adverse events, and this was also considered
“important.” RCTs of any duration beyond 12 weeks were included.
Outcomes were extracted at 3e4 months, 1 year, and 3 years. Studies
were excluded if there were <50 participants.
The systematic literature search was conducted in PubMed,
MEDLINE, Embase, and Cochrane databases; see Supplementary
Appendix S3 (Search terms and strategy). All studies reported in a
language other than English were excluded. The title and abstract of
studies were screened by two assessors (ZZNY and ZKJ-L), with any
disagreement reviewed by a third assessor (CHS). Selected RCTs
were distributed amongst the co-authors for detailed appraisal and
extraction of data using a standardized data extraction tool and the
extractions checked by another (LSE).
Data analysis and quality assessment of evidence
NMA was performed using a random-effects model within a fre-
quentist approach in Stata 13 (Stata Corp, College Station, TX) using
the network command (Chaimani et al., 2014; White, 2011). NMA
synthesizes direct and indirect evidence in a network of trials that
compare multiple interventions (Mills et al., 2013). NMA increases
the precision in the estimates and produces a relative ranking of all
treatments for the studied outcome (Bucher et al., 1997; Salanti
et al., 2011).
Geometry of the networks was assessed through visual inspection
of network maps. Summary results were presented as an odds ratio,
or mean, with a 95% CI. Predictive intervals were calculated to
provide an interval within which the estimate of a future study would
be expected. Cumulative ranking probability plots were used to
represent the ranking probabilities of the various treatments with a
visual estimation of their uncertainty. Rankings were quantified by
the SUCRAs that express the percentage (0e100%) of efficacy/safety
each treatment has compared with an ideal treatment ranked always
first without uncertainty (Salanti et al., 2011). The larger the SUCRA
value, the better the rank. Outcomes were jointly ranked using the
hierarchical cluster analysis of the SUCRA values of each outcome
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using the clusterank command. Cluster analysis is an exploratory
data mining technique for grouping objects based on their features
so that the degree of association is high between members of the
same group and low between members of different groups
(Chaimani et al., 2013). Absolute effects were calculated from
relative effects estimates based on the assumed control risk across all
studies of that comparator using GRADEPro GDT (McMaster Uni-
versity). Numbers needed to treat or harm were calculated as the
reciprocal of the corresponding risk.
Study quality was evaluated using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions
(Higgins et al., 2011). Heterogeneity and inconsistency were eval-
uated using visual inspection of the forest plots. Inconsistency was
also tested formally using an overall chi-squared test of inconsis-
tency and through loop-specific inconsistency plots and calculation
of an inconsistency factor (Chaimani et al., 2013). Additional sub-
group analysis was performed restricted to data on licensed biologic
doses. Publication bias was assessed with the aid of comparison-
adjusted funnel plots, which show the difference between each
study’s estimate and the direct summary effect for the respective
comparison in terms of newer versus older treatments (Chaimani
et al., 2013).
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